SCHEMBL13469508

SCHEMBL13469508

CCOCCn1c(=O)c(C#N)c(O)c2ccccc21

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.48
KDM4E B2RXH2 9/20 0.48
GAA P10253 1/20 0.48
LMNA P02545 4/20 0.47
ALDH1A1 P00352 7/20 0.46
HPGD P15428 3/20 0.46
HTT P42858 2/20 0.46
POLB P06746 1/20 0.45
HSD17B10 Q99714 1/20 0.45
RCE1 Q9Y256 1/20 0.45
MAPT P10636 2/20 0.44
HTR3A P46098 1/20 0.44
MAPK1 P28482 1/20 0.43
STAT3 P40763 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9216581 0.85 KDM4E (0.64) TDP1KDM4EGAALMNAALDH1A1
SCHEMBL13469365 0.85 L3MBTL1 (0.46) TDP1KDM4EGAALMNAALDH1A1
SCHEMBL23411350 0.83 KDM4E (0.64) KDM4EGAALMNAALDH1A1HPGD
SCHEMBL29891520 0.83 KDM4E (0.64) KDM4EGAALMNAALDH1A1HPGD
SCHEMBL6232527 0.80 ALDH1A1 (0.52) KDM4EGAALMNAALDH1A1HPGD
SCHEMBL7162258 0.79 KDM4E (0.47) TDP1KDM4EGAALMNAALDH1A1
SCHEMBL16534208 0.77 TDP1 (0.41) TDP1LMNAALDH1A1HTTMAPK1
SCHEMBL568368 0.77 ALDH1A1 (0.56) KDM4EGAALMNAALDH1A1HPGD
SCHEMBL30099730 0.77 ALDH1A1 (0.56) KDM4EGAALMNAALDH1A1HPGD
SCHEMBL13469509 0.76 TDP1 (0.38) TDP1GAALMNAHTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3354640-A2 MIF INHIBITORS AND THEIR USES Innovimmune Biotherapeutics, Inc. (US) 2018-08-01 EP disclosed
EP-3354640-A2 MIF INHIBITORS AND THEIR USES Innovimmune Biotherapeutics, Inc. (US) 2018-08-01 EP disclosed
EP-2696682-B1 MIF INHIBITORS AND THEIR USES INNOVIMMUNE BIOTHERAPEUTICS INC (US) 2018-03-21 EP disclosed
EP-2696682-B1 MIF INHIBITORS AND THEIR USES INNOVIMMUNE BIOTHERAPEUTICS INC (US) 2018-03-21 EP disclosed
US-9133164-B2 MIF inhibitors and their uses INNOV88 LLC (US) 2015-09-15 US disclosed
US-20150065480-A1 MIF INHIBITORS AND THEIR USES INNOVIMMUNE BIOTHERAPEUTICS, INC. (US) 2015-03-05 US disclosed
WO-2012142498-A2 MIF INHIBITORS AND THEIR USES INNOVIMMUNE BIOTHERAPEUTICS, INC. (US) 2012-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150065480-A1 MIF INHIBITORS AND THEIR USES MIF, SERPINB1, HMGB2 TDP1 3472/4885KDM4E 4189/4885GAA 1974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.